



Breadcrumb

1. [Home](#)

Entity Print



Christian Chabannon
CTIWP Chair
France

Major achievements

The CTIWP activities and projects continue to grow along two main avenues:

1. Exploring biological phenomenon that underlie clinical efficacy and safety issues in allogeneic hematopoietic cell transplantation, mostly used a s

immunotherapy of haematological cancers, and of autologous hematopoietic cell transplantation to support the administration of high-dose consolidation chemotherapy in selected subsets of patients with solid tumours.

2. Pave the way for accelerated access and thorough evaluation of the new generation of Immune Effector Cells (IECs) based therapies, of which autologous CAR-T cells remain the most publicized. Registrations of CAR-T Cells treated patients continues and now nears 2,000 patients. The CTIWP largely contributed to the production of the first reports for Post-Authorization Safety Studies sent to Novartis and Kite / Gilead, using aggregated data, while the CTO worked hard to establish contracts with CAR-T Cells treating centers in order to establish conditions that allow secondary use of data and center compensation, with a view to further improve the quality and utility of collected data. Scientific priorities, data access, Cellular Therapy Form revisions, harmonization of center qualification criteria and processes are some of the topics and work packages included in the GoCAR-T initiative that aims to bring all interested parties in the field of Immune Effector Cells – particularly CAR-T Cells – to join forces and cooperate in order to fully measure the medical value of these innovative therapies and remain competitive with our colleagues in the rest of the world.

The CTIWP also contributed to the EBMT COVID-19 Task Force, looking at some of the disruptive consequences of the pandemic on the supply chains for hematopoietic cell transplants and hematopoietic cellular therapies, as well as clinical consequences for patients / recipients and donors.

Principal research studies

[Donor lymphocyte infusions after haploidentical stem cell transplantation: a study on behalf of the cellular therapy & immunobiology working party of the EBMT](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

-

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[Type of Stem Cell Treatment](#)

-

[Principal investigator](#)

[Nicole Santoro](#)

[Monitoring virus-specific T-cell response in allogeneic hematopoietic stem cell transplant recipients](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

-

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[Type of Stem Cell Treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Raffaella Greco](#)

Key publications

[2021](#)

[Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[Infectious Diseases Working Party \(IDWP\)](#)

[1st listed author](#)

[Sara Ghorashian](#)

[Journal](#)

[Bone Marrow Transplant.](#)

[2020](#)

[Use of the HLA-B leader to optimize cord-blood transplantation](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[1st listed author](#)

[Effie W Petersdorf](#)

[Journal](#)

[Haematologica.](#)

[2021](#)

[Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study](#)

Group

Cellular Therapy & Immunobiology Working Party (CTIWP)

1st listed author

Massimo Martino

Journal

Bone Marrow Transplant.

2021

Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation:
a study on behalf of the CTIWP of the EBMT

Group

Cellular Therapy & Immunobiology Working Party (CTIWP)

1st listed author

Loredana Ruggeri


Journal

Bone Marrow Transplant.

See the full list of the CTIWP 2021 publications



Impact factor (Cellular Therapy & Immunobiology)



2019 2020 2021

| | | | |
|-----------------------------|----|---|---|
| Oral presentations | 16 | 8 | 4 |
| Poster presentations | 2 | 1 | 2 |
| Educational events | 6 | 4 | 5 |



[Event](#)

[**Cellular Therapy & Immunobiology Working Party Workshop**](#)



[Event](#)

[**3rd European CAR T-cell Meeting \[Virtual\]**](#)

[Feb 04, 2021 - Feb 06, 2021 / Virtual Meeting](#)

[Discover more](#)